Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset VEEV

Coverage 92,387 Raw stories ingested 7,962 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,728 Assets with fetched stories

Cryptocurrencies BTC 4,261 ETH 3,079 SOL 1,751 XRP 1,689 USDC 969 HYPE 828

Stocks SPCX 879 MU 724 NVDA 684 MSFT 558 GOOGL 531 TSLA 504

Commodities GOLD 159 SILVER 93 OIL 51 PLATINUM 5 PALLADIUM 2 COPPER 1

Forex EURUSD 147 GBPUSD 143 USDCAD 51 USDJPY 37 AUDUSD 33 NZDUSD 23

1,681 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 waiting Pipeline agents

FMP Stock News Fetch every minute 18s ago
FMP Forex News Fetch every 5 min 2m ago
CoinGecko News Fetch every 5 min 2m ago
FIO Stock News Fetch every 10 min 6m ago
Patria Stock News Fetch every 10 min 6m ago
Editorial rewrite Rewrite every minute 18s ago
Asset sync Assets every 1 hour 56m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-07-15 15:54 10d ago Published 2026-07-15 10:05 10d ago	Veeva Systems překonala odhady díky růstu služeb předplatného Veeva Systems v 1. čtvrtletí fiskálního roku 2027 překonala odhady zisku i tržeb díky růstu služeb předplatného. Vault CRM má přes 150 aktivních zákazníků a více než 40 migrací. VEEV Veeva Systems	FMP Stock News	72
Original source text Key Takeaways VEEV topped Q1 fiscal 2027 earnings and revenue estimates, led by Subscription services growth.VEEV's Vault CRM has 150 live customers, 40 migrations and over 80% overall win rate.VEEV is expanding AI offerings, with Ostro serving over 50 brands and Vault AI due in August. Veeva Systems Inc. (VEEV - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid first-quarter fiscal 2027 performance and CRM migrations, is expected to contribute further. However, market saturation remains a cause for concern. This Zacks Rank #3 (Hold) company’s shares have lost 13.5% in the year-to-date period compared with the 5.9% decline of the industry. The S&P 500 composite has increased 9.7% during the said time frame. The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $31.97 billion. The company anticipates 35% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 5.5%. Image Source: Zacks Investment Research Reasons Favoring VEEV’s GrowthDiversified Platform Driving Durable Growth:Veeva Systems’ long-term growth story is increasingly tied to its position at the center of life sciences digital transformation. The company operates across a broad set of markets spanning clinical development, quality management, regulatory operations, safety, commercial engagement and data analytics. Veeva Systems’ Development Cloud portfolio is particularly well-positioned as pharmaceutical companies seek integrated platforms that connect clinical data, trial operations, quality processes and regulatory functions within a unified ecosystem. Growth is being fueled by newer product areas that remain in the early stages of penetration, including clinical data management, randomization and trial supply management, drug safety and laboratory information management systems. Management believes these businesses have a significant runway as customers increasingly favor end-to-end platforms over fragmented point solutions. Enterprise CRM Migrations Expanding Account Footprint: Vault CRM adoption continues to build as large customers move off legacy CRM deployments and standardize commercial workflows. Management highlighted recent global selections from Teva and Merck KGaA and noted that Veeva Systems has secured 10 wins compared with six for Salesforce, within its defined top 20 cohort, with four decisions still pending. The company also cited an overall Vault CRM win rate above 80% and more than 150 customers live, supported by over 40 completed migrations. This installed base creates a multi-year services and subscription runway and should support the attachment of adjacent commercial applications. Strong Q1 Results: Veeva Systems exited the first quarter of fiscal 2027 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The uptick in both top and bottom lines and robust performance by the Subscription services segment during the quarter were impressive. The uptick in Professional services and others’ revenues also bodes well. Veeva Systems continues to strengthen its position in life sciences software through rapid innovation in artificial intelligence and expanding customer adoption. During the fiscal first quarter, the company significantly advanced its industry-specific AI strategy. Ostro, acquired in March, is now delivering compliant conversational AI for more than 50 brands, while Vault AI remains on track for deployment across all Vault applications in August. Factor That May Offset VEEV’s GainsMarket Saturation: The life sciences industry, Veeva Systems' primary market for its CRM solutions, is facing increasing saturation as digital transformation and CRM adoption have become widespread across pharmaceutical and biotech companies. Many large enterprises have already implemented Veeva Systems' CRM software or similar solutions, leaving fewer untapped opportunities for new customer acquisition. Additionally, as smaller biotech firms and generics manufacturers enter the market, they may seek more cost-effective or niche CRM alternatives rather than Veeva Systems' premium offerings. This saturation, combined with heightened competition from both traditional CRM providers and emerging AI-powered platforms, could limit Veeva Systems' ability to maintain its historical CRM sales growth rates. Estimate TrendVeeva Systems is witnessing a stable estimate revision trend for fiscal 2027. In the past 30 days, the Zacks Consensus Estimate for fiscal 2027 earnings per share (EPS) has remained stable at $9.05. The Zacks Consensus Estimate for second-quarter fiscal 2027 revenues is pegged at $904.1 million, indicating a 14.6% improvement from the year-ago quarter’s reported number. The EPS estimate for the second quarter of fiscal 2027 is pinned at $2.22, implying a 11.6% improvement year over year. Key PicksSome better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. West Pharmaceutical reported first-quarter 2026 earnings per share of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%. Intuitive Surgical reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%. Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Cardinal Health reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%. Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
	Saved 2026-07-03 18:36 22d ago Published 2026-07-03 12:31 22d ago	Veeva zvýšila výhled po silném čtvrtletí Veeva Systems oznámila za 1. fiskální čtvrtletí tržby 882,9 milionu USD a upravený EPS 2,24 USD, obojí nad odhady. Pro 2. čtvrtletí i celý fiskální rok 2027 zvýšila výhled tržeb i zisku. VEEV Veeva Systems	FMP Stock News	78
Original source text It has been about a month since the last earnings report for Veeva Systems (VEEV - Free Report) . Shares have added about 7.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Veeva due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Veeva Systems Q1 Earnings & Revenues Beat, Operating Margin RiseVeeva Systems reported adjusted earnings per share of $2.24 for the first quarter of fiscal 2027, which increased 13.7% from the year-ago figure of $1.74. Adjusted earnings per share beat the Zacks Consensus Estimate by 5.2%. GAAP earnings per share in the fiscal first quarter was $1.57, up 14.6% from the year-ago period’s $1.37. VEEV’s Q1 Revenue DetailsIn the quarter under review, the company’s revenues totaled $882.9 million, beating the Zacks Consensus Estimate by 2.9%. On a year-over-year basis, the top line improved 16.3%. The fiscal first-quarter top line was driven by Veeva Systems’ robust segmental performance. Segmental Analysis of VEEVVeeva Systems derives revenues from two operating segments: Subscription services and Professional services and other. In the fiscal first quarter, Subscription services revenues improved 15% from the year-ago quarter to $730.2 million. Per management, this uptick was driven by both its established and newer solutions. Professional services and other revenues increased 22.9% year over year to $152.8 million. Q1 Margin Performance by VEEVIn the quarter under review, Veeva Systems’ gross profit improved 13.1% year over year to $662 million. However, the gross margin contracted 220 basis points (bps) to 74.9%. Sales and marketing expenses increased 12.7% year over year to $111.1 million. Research and development (R&D) expenses rose 13.2% year over year to $208.3 million, while general and administrative expenses increased 0.9% year over year to $69.5 million. Total operating expenses of $388.9 million increased 10.6% year over year. Operating profit totaled $273.1 million, which increased 16.8% from the prior-year quarter. The operating margin in the fiscal first quarter expanded 20 bps to 30.9%. VEEV’s Financial PositionThe company exited first-quarter fiscal 2027 with cash and cash equivalents and short-term investments of $7.31 billion compared with $6.56 billion at the fiscal fourth quarter of 2026-end. Net cash provided by operating activities at the end of the quarter was $1.13 billion compared with $877.2 million a year ago. Q2 & FY27 Guidance Provided by VEEVVeeva Systems has issued its financial outlook for the fiscal second quarter and fiscal 2027. For the fiscal second quarter, the company expects total revenues between $902 million and $905 million. The Zacks Consensus Estimate is currently pegged at $886.8 million. Subscription revenues are estimated to be approximately $754 million, and revenues for Professional services and other are expected to be in the range of $148-$151 million for the fiscal second quarter. For the fiscal second quarter, adjusted earnings per share is anticipated to be between $2.21 and $2.22. The Zacks Consensus Estimate is pegged at $2.19. Veeva Systems now expects revenues for fiscal 2027 between $3,635 million and $3,645 million. The Zacks Consensus Estimate is currently pegged at $3.59 billion. For fiscal 2027, Subscription revenues are now expected to be approximately $3,060 million. This consists of Commercial Solutions’ subscription revenues of around $1,395 million and R&D Solutions’ subscription revenues of approximately $1,665 million. Professional services and other revenues for fiscal 2027 are now expected to be between $575 million and $580 million. Adjusted earnings per share for fiscal 2027 is now expected to be approximately $9.05. The Zacks Consensus Estimate is pegged at $8.86. How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates revision. VGM ScoresAt this time, Veeva has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with a D. Charting a somewhat similar path, the stock was allocated a score of C on the value side, putting it in the middle 20% for value investors. Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in. OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, Veeva has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
	Saved 2026-06-29 18:44 26d ago Published 2026-06-29 13:31 26d ago	Veeva koupila Copli a spustila Falcon MLR Veeva Systems koupila Copli a spustila Falcon MLR, AI nástroj pro rychlejší kontrolu a schvalování obsahu v oblasti life sciences. Firma tvrdí, že může do pěti let odstranit přes 70 % manuální práce v MLR. VEEV Veeva Systems	FMP Stock News	86
Original source text Key Takeaways VEEV acquired Copli and launched Falcon MLR to automate life sciences content reviews.Falcon MLR integrates with PromoMats to check content against labels and country rules.VEEV says Falcon MLR could eliminate over 70% of manual MLR labor in five years. Veeva Systems (VEEV - Free Report) has strengthened its artificial intelligence (AI)-driven commercial content capabilities with the acquisition of Copli, a pioneer in agentic medical, legal and regulatory (MLR) solutions for the life sciences industry. Alongside the acquisition, the company launched Veeva Falcon MLR, an AI-powered solution designed to accelerate content review and approval processes. From an investor's standpoint, the acquisition expands Veeva's AI portfolio and enhances the value proposition of its commercial cloud offerings. By embedding agentic automation into the MLR workflow, the company is likely to drive stronger customer adoption, deepen platform stickiness and create additional cross-selling opportunities, which could support long-term revenue growth and strengthen its competitive position in the life sciences software market. Likely Trend of VEEV Stock Following the NewsShares of VEEV have traded flat since the announcement on June 23. In the year-to-date period, shares of the company lost 23.3% compared with the industry’s 10.9% decline. The S&P 500 increased 7.1% in the same time frame. The launch of Veeva Falcon MLR is expected to strengthen Veeva's long-term growth prospects by expanding its AI-driven product portfolio and increasing the strategic value of its Commercial Cloud platform. As pharmaceutical and biotechnology companies seek to accelerate content approvals while maintaining regulatory compliance, Falcon MLR can help streamline one of the industry's most time-consuming workflows through agentic automation. Its seamless integration with Veeva PromoMats is likely to drive broader customer adoption, improve client retention and create cross-selling opportunities across Veeva's installed base, reinforcing recurring subscription revenues and the company's leadership in life sciences software. VEEV currently has a market capitalization of $27.84 billion. Image Source: Zacks Investment Research More on the NewsVeeva Falcon MLR is an agentic MLR solution that automates the review of promotional and medical content for life sciences companies. Built on Copli's technology and integrated with Veeva PromoMats, the solution conducts compliance checks against approved product labels and country-specific regulations, enabling marketing teams, MLR reviewers and agencies to streamline the review and approval process. According to Veeva, Falcon MLR has the potential to eliminate more than 70% of manual MLR labor over the next five years, significantly shortening review cycles while improving operational efficiency. The launch is expected to primarily strengthen Veeva's Commercial Cloud business, particularly its Content Management portfolio led by PromoMats. PromoMats is widely used by pharmaceutical and biotechnology companies to manage the creation, review, approval and distribution of compliant promotional content. By embedding agentic AI directly into this workflow, Veeva enhances the functionality of an already mission-critical application, increasing customer value while making its commercial content ecosystem more intelligent and difficult to replace. The addition of Falcon MLR also complements Veeva's broader Falcon AI portfolio, reinforcing the company's strategy of integrating AI capabilities across its cloud applications. The acquisition of Copli further expands Veeva's AI expertise and accelerates the commercialization of agentic automation across the life sciences industry. As demand for AI-powered compliance and content management solutions continues to rise, Falcon MLR positions Veeva to capture incremental growth opportunities while strengthening its competitive moat in life sciences software. Favorable Industry Prospect for VEEVPer a report by Grand View Research, the global agentic AI in healthcare market size was estimated at $538.51 million in 2024 and is projected to reach $4.96 billion by 2030, expanding at a CAGR of 45.56%. The rising automation of repetitive tasks, growing focus on cost and resource optimization, and increasing adoption of enhanced patient care solutions are factors contributing to market growth. A Recent Development by VEEVRecently, VEEV announced the launch of Veeva EHS, a new environmental, health and safety application within its Veeva Quality Cloud. The solution is designed to help manufacturing and testing sites proactively identify, manage and mitigate operational and environmental risks while strengthening global compliance readiness. Management stated that Veeva EHS delivers an advanced and automated approach to environmental, health and safety processes. It enables EHS teams to free up time and ensures quick and accurate execution. VEEV’s Zacks Rank & Key PicksCurrently, VEEV carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) . Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12 per share, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%. West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%. Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%. ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
	Saved 2026-06-26 16:34 29d ago Published 2026-06-26 12:00 29d ago	Veeva spustila EHS v Quality Cloud Veeva spustila Veeva EHS v rámci Quality Cloud pro řízení provozních a environmentálních rizik a compliance. Akcie VEEV po oznámení klesly o 2 %. VEEV Veeva Systems	FMP Stock News	78
Original source text Key Takeaways Veeva launched EHS within Quality Cloud to help sites manage operational and environmental risks.VEEV shares fell 2% after the news, with the stock down 29.2% year to date.Veeva EHS automates incident reporting, investigations and compliance workflows on one platform. Veeva Systems (VEEV - Free Report) recently announced the launch of Veeva EHS, a new environmental, health and safety application within its Veeva Quality Cloud. The solution is designed to help manufacturing and testing sites proactively identify, manage and mitigate operational and environmental risks while strengthening global compliance readiness. Management stated that Veeva EHS delivers an advanced and automated approach to environmental, health and safety processes. It enables EHS teams to free up time and ensures quick and accurate execution. The company believes organizations replacing legacy EHS systems with a unified platform will gain real-time transparency into leading indicators of risk for more informed decisions and a proactive approach to prevention. Veeva EHS is expected to be available to early adopters in August 2026. Likely Trend of VEEV Stock Following the NewsFollowing the announcement, VEEV shares lost 2% at yesterday’s closing. Year to date, the stock has declined 29.2%, underperforming the industry’s 15.2% fall and the S&P 500’s 7.3% rise. The launch of Veeva EHS is expected to strengthen Veeva’s position in the EHS software market by expanding its Quality Cloud portfolio. The unified platform can drive higher customer adoption, improve cross-selling opportunities and increase recurring revenues. Its automation, real-time risk visibility and integrated compliance capabilities also enhance Veeva's competitive advantage over legacy EHS solution providers, supporting long-term business growth. VEEV currently has a market capitalization of $26.21 billion. Image Source: Zacks Investment Research More on Veeva EHSVeeva EHS enables organizations to report safety incidents in real time, manage investigations from start to finish and automate compliance workflows within a single platform. The solution integrates with Veeva QMS and Veeva Training, allowing safety events to automatically create quality deviations and assign relevant training. This eliminates duplicate data entry, streamlines workflows and helps organizations maintain compliance. According to Bobbie Grant, Global Senior EHS Manager at Thermo Fisher Scientific, a modern EHS platform with unified data and a seamless user experience across the entire EHS workflow can significantly improve site efficiency. Grant added that Veeva provides an advanced solution that can maintain data integrity and provide the foundation for AI-driven capabilities to reduce risk over time. Industry Prospects Favoring the MarketGoing by the data provided by Research and Markets, the environmental health and safety (EHS) software market is valued at $8.9 billion in 2026 and is expected to witness a CAGR of 8.1% through 2030. Factors like the stringent regulatory requirements that healthcare and life science organizations must navigate, digital transformation initiatives in healthcare and life sciences, a growing focus on workplace safety and risk reduction, and the integration of AI and machine learning are boosting the market’s growth. Other NewsVeeva recently acquired Copli, a pioneer in agentic medical, legal and regulatory (MLR) solutions for the life sciences industry. Copli is available as Veeva Falcon MLR, an agentic MLR solution that significantly accelerates content review with the potential to eliminate 70% or more of manual MLR labor within five years. VEEV’s Zacks Rank & Key PicksCurrently, VEEV has a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) . BrightSpring Health, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank stocks here. BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%. Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%. Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%. Intuitive Surgical has a long-term estimated growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.